BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 22688190)

  • 1. Active vaccination with ankyrin G reduces β-amyloid pathology in APP transgenic mice.
    Santuccione AC; Merlini M; Shetty A; Tackenberg C; Bali J; Ferretti MT; McAfoose J; Kulic L; Bernreuther C; Welt T; Grimm J; Glatzel M; Rajendran L; Hock C; Nitsch RM
    Mol Psychiatry; 2013 Mar; 18(3):358-68. PubMed ID: 22688190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Active immunization of mice with an Abeta-Hsp70 vaccine.
    Koller MF; Mohajeri MH; Huber M; Wollmer MA; Roth Z'graggen BV; Sandmeier E; Moritz E; Tracy J; Nitsch RM; Christen P
    Neurodegener Dis; 2004; 1(1):20-8. PubMed ID: 16908970
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dispersible amyloid β-protein oligomers, protofibrils, and fibrils represent diffusible but not soluble aggregates: their role in neurodegeneration in amyloid precursor protein (APP) transgenic mice.
    Rijal Upadhaya A; Capetillo-Zarate E; Kosterin I; Abramowski D; Kumar S; Yamaguchi H; Walter J; Fändrich M; Staufenbiel M; Thal DR
    Neurobiol Aging; 2012 Nov; 33(11):2641-60. PubMed ID: 22305478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse.
    Schenk D; Barbour R; Dunn W; Gordon G; Grajeda H; Guido T; Hu K; Huang J; Johnson-Wood K; Khan K; Kholodenko D; Lee M; Liao Z; Lieberburg I; Motter R; Mutter L; Soriano F; Shopp G; Vasquez N; Vandevert C; Walker S; Wogulis M; Yednock T; Games D; Seubert P
    Nature; 1999 Jul; 400(6740):173-7. PubMed ID: 10408445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A subcutaneous cellular implant for passive immunization against amyloid-β reduces brain amyloid and tau pathologies.
    Lathuilière A; Laversenne V; Astolfo A; Kopetzki E; Jacobsen H; Stampanoni M; Bohrmann B; Schneider BL; Aebischer P
    Brain; 2016 May; 139(Pt 5):1587-604. PubMed ID: 26956423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
    Geylis V; Steinitz M
    Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAGE does not affect amyloid pathology in transgenic ArcAbeta mice.
    Vodopivec I; Galichet A; Knobloch M; Bierhaus A; Heizmann CW; Nitsch RM
    Neurodegener Dis; 2009; 6(5-6):270-80. PubMed ID: 20145420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IFN-γ Production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease.
    Browne TC; McQuillan K; McManus RM; O'Reilly JA; Mills KH; Lynch MA
    J Immunol; 2013 Mar; 190(5):2241-51. PubMed ID: 23365075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abeta peptide immunization restores blood-brain barrier integrity in Alzheimer disease.
    Dickstein DL; Biron KE; Ujiie M; Pfeifer CG; Jeffries AR; Jefferies WA
    FASEB J; 2006 Mar; 20(3):426-33. PubMed ID: 16507760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunotherapy for Alzheimer's disease.
    Steinitz M
    Immunotherapy; 2009 May; 1(3):461-9. PubMed ID: 20635962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoid receptor 1 deficiency in a mouse model of Alzheimer's disease leads to enhanced cognitive impairment despite of a reduction in amyloid deposition.
    Stumm C; Hiebel C; Hanstein R; Purrio M; Nagel H; Conrad A; Lutz B; Behl C; Clement AB
    Neurobiol Aging; 2013 Nov; 34(11):2574-84. PubMed ID: 23838176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease peptide epitope vaccine reduces insoluble but not soluble/oligomeric Abeta species in amyloid precursor protein transgenic mice.
    Petrushina I; Ghochikyan A; Mktrichyan M; Mamikonyan G; Movsesyan N; Davtyan H; Patel A; Head E; Cribbs DH; Agadjanyan MG
    J Neurosci; 2007 Nov; 27(46):12721-31. PubMed ID: 18003852
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Active immunization trial in Abeta42-injected P301L tau transgenic mice.
    Kulic L; Kurosinski P; Chen F; Tracy J; Mohajeri MH; Li H; Nitsch RM; Götz J
    Neurobiol Dis; 2006 Apr; 22(1):50-6. PubMed ID: 16289870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease.
    Schiltz JG; Salzer U; Mohajeri MH; Franke D; Heinrich J; Pavlovic J; Wollmer MA; Nitsch RM; Moelling K
    J Mol Med (Berl); 2004 Oct; 82(10):706-14. PubMed ID: 15241501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer's disease-like neuropathology.
    Bard F; Barbour R; Cannon C; Carretto R; Fox M; Games D; Guido T; Hoenow K; Hu K; Johnson-Wood K; Khan K; Kholodenko D; Lee C; Lee M; Motter R; Nguyen M; Reed A; Schenk D; Tang P; Vasquez N; Seubert P; Yednock T
    Proc Natl Acad Sci U S A; 2003 Feb; 100(4):2023-8. PubMed ID: 12566568
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
    Clausen A; Xu X; Bi X; Baudry M
    J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer's disease mice.
    Park MH; Lee JK; Choi S; Ahn J; Jin HK; Park JS; Bae JS
    Brain Res; 2013 Sep; 1529():113-24. PubMed ID: 23831521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunotherapy for Alzheimer's disease: from anti-β-amyloid to tau-based immunization strategies.
    Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
    Immunotherapy; 2012 Feb; 4(2):213-38. PubMed ID: 22339463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice.
    Bard F; Fox M; Friedrich S; Seubert P; Schenk D; Kinney GG; Yednock T
    Exp Neurol; 2012 Nov; 238(1):38-43. PubMed ID: 22892246
    [TBL] [Abstract][Full Text] [Related]  

  • 20. beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip technology.
    Vehmas AK; Borchelt DR; Price DL; McCarthy D; Wills-Karp M; Peper MJ; Rudow G; Luyinbazi J; Siew LT; Troncoso JC
    DNA Cell Biol; 2001 Nov; 20(11):713-21. PubMed ID: 11788049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.